H.D. Smith subsidiary launches new website
WOOD DALE, Ill. Smith Medical Partners, a business focused on specialty pharmaceutical distribution and solutions, announced the launch of its new company website.
The H.D. Smith subsidiary said its new site, Smpspecialty.com, features a user-friendly platform that includes audience-specific landing pages, including relevant products and FAQs tailored for unique segments of the healthcare industry.
Additionally, the site also will feature Smith Medical Partners news, reimbursement announcements, recall postings and industry developments, as well as e-newsletters that are tailored for multiple specialty practices, placing Smith Medical Partners customers among the first to receive details on new product launches, special purchasing opportunities and program information.
“Our online visitors will now experience a more comprehensive and vibrant view of Smith Medical Partners,” said Smith Medical Partners VP David DuRoss. “We have taken a strategic approach to providing rich content in an accessible and streamlined layout.”
Actavis gets FDA approval for generic Cozaar
MORRISTOWN, N.J. Actavis has received regulatory approval from the Food and Drug Administration for its high blood pressure drug.
The drug maker said its losartan potassium tablets, USP, will be available in 25-mg, 50-mg and 100-mg strengths. The drug is a generic version of Merck’s Cozaar.
Losartan potassium tablets, USP, had sales of approximately $940 million for the 12 months ended June 30, according to IMS Health.
Express Scripts looks to curb nonadherence among patients
ST. LOUIS Pharmacy benefit manager Express Scripts said it has created a way to accurately predict which patients were most at risk of not adhering to their medications.
The PBM announced Monday that it had created a computer model that could predict whether a patient would fail to take medications as prescribed up to a year in advance, allowing early intervention to improve adherence. The company said patent protection for the model is pending. According to Express Scripts’ 2009 Drug Trend Report, nonadherence results in $106 billion being wasted on increased medical costs every year.
“The problem of nonadherence isn’t new — it’s easy to walk through a hospital and identify people who would not be there if they had simply taken their medications,” Express Scripts chief medical officer Steven Miller said. “But our new predictive models allow us to do something that wasn’t possible before: better identify those patients before they run into trouble and tailor practical, patient-centric solutions that target the specific factors that put them at risk for nonadherence.”